Hinge Health, Inc. (HNGE) Key Metrics
HNGE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.00B
- Enterprise value
- $7.06B
- P/E (TTM)
- 32.7
- Forward P/E
- 33.0
- PEG ratio
- —
- Price / sales
- 11.1
- Price / book
- 21.6
- EV / EBITDA
- 71.8
- Dividend yield
- —
- Beta
- —
HNGE key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsHNGE returns How much profit the business earns on the capital it uses.
HNGE per-share figures Results divided by the shares outstanding at year-end.
HNGE financial health Debt, liquidity and how easily interest is covered.
HNGE efficiency & capital use Working capital cycle and where the cash goes.
HNGE valuation history
HNGE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HNGE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HNGE cash returned to shareholders
HNGE price vs earnings per share
HNGE key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $3.79B | — | — |
| Enterprise value | $3.44B | — | — |
| Price / sales | 6.5 | — | — |
| Price / book | 10.0 | — | — |
| Price / free cash flow | 22.2 | — | — |
| Price / operating cash flow | 22.1 | — | — |
| EV / sales | 5.8 | — | — |
| EV / free cash flow | 20.1 | — | — |
| Earnings yield | −13.9% | — | — |
| Free cash flow yield | 4.5% | — | — |
| Shareholder yield (dividends + buybacks) | 1.7% | — | — |
| Share price at fiscal year-end | $46.45 | — | — |
| Per share | |||
| Revenue per share | $7.20 | $5.00 | $3.75 |
| Earnings per share | −$6.47 | −$0.15 | −$1.39 |
| Operating cash flow per share | $2.10 | $0.63 | −$0.82 |
| Free cash flow per share | $2.09 | $0.58 | −$0.88 |
| Cash per share | $4.45 | $5.98 | $5.43 |
| Book value per share | $4.63 | $5.34 | $5.48 |
| Tangible book value per share | $3.82 | $4.53 | $4.66 |
| Capex per share | $0.01 | $0.05 | $0.06 |
| Debt per share | $0.10 | $0.14 | $0.20 |
| Shares outstanding | 81.7M | 78.0M | 78.0M |
| Change in shares outstanding | +4.7% | +0.0% | — |
| Returns & profitability | |||
| Return on equity (ROE) | −132.9% | −2.8% | −25.3% |
| Return on invested capital (ROIC) | — | — | −524.6% |
| Return on assets (ROA) | −74.5% | −1.8% | −17.4% |
| Return on tangible assets | −77.9% | −2.0% | −19.4% |
| Free cash flow margin | 29.0% | 11.6% | −23.4% |
| Financial health | |||
| Total debt | $8.0M | $11.1M | $15.7M |
| Cash & short-term investments | $363.9M | $466.6M | $423.4M |
| Net debt | −$355.8M | −$455.5M | −$407.6M |
| Debt / equity | 0.02 | 0.03 | 0.04 |
| Debt / assets | 0.01 | 0.02 | 0.03 |
| Current ratio | 1.47 | 2.34 | 2.88 |
| Quick ratio | 1.43 | 2.30 | 2.81 |
| Working capital | $171.5M | $334.1M | $345.7M |
| Invested capital | $22.7M | −$38.8M | $19.7M |
| Tangible asset value | $311.9M | $353.3M | $363.5M |
| Net current asset value | $167.7M | $326.9M | $334.6M |
| Graham net-net per share | $0.67 | $3.17 | $3.46 |
| Capital allocation | |||
| Share buybacks (net) | $65.0M | $0 | $0 |
| Dividends + buybacks / free cash flow | 38.1% | 0.0% | — |
| Capex / revenue | 0.1% | 1.0% | 1.6% |
| Capex / operating cash flow | 0.4% | 7.7% | — |
| Capex / depreciation | 0.14 | 0.63 | 0.82 |
| Stock-based compensation / revenue | 109.4% | 0.2% | 0.6% |
| R&D / revenue | 62.6% | 25.8% | 37.6% |
| SG&A / revenue | 108.8% | 58.3% | 73.3% |
| Efficiency | |||
| Days sales outstanding | 33.7 | 41.6 | 58.1 |
| Days of inventory on hand | 40.8 | 49.1 | 49.2 |
| Days payables outstanding | 176.5 | — | — |
| Cash conversion cycle (days) | -102.0 | — | — |
| Receivables turnover | 10.83 | 8.77 | 6.29 |
| Payables turnover | 2.07 | — | — |
| Inventory turnover | 8.94 | 7.43 | 7.41 |
| Asset turnover | 0.83 | 0.60 | 0.47 |
| Average receivables | $54.3M | $44.5M | $46.6M |
| Average payables | $57.3M | — | — |
| Average inventory | $13.3M | $12.1M | $13.3M |
| Intangibles / total assets | 8.9% | 9.4% | 10.2% |
Computed from HNGE's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HNGE valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 32.7 and the forward P/E is 33.0. Hinge Health earned a return on equity of −132.9% in fiscal 2025. It ended the year with $8.0 million of debt and $363.9 million in cash and short-term investments, a net cash position of $355.8 million. It returned $65.0 million to shareholders: $0 in dividends and $65.0 million in share buybacks, 38% of free cash flow.
See the HNGE income statement, the HNGE chart for price history, or the HNGE stock overview for the latest quote and news.
HNGE key metrics FAQ
What is Hinge Health's P/E ratio?
Hinge Health's trailing P/E ratio is 32.7 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 33.0. At the end of fiscal 2025 it was —.
What is Hinge Health's return on equity?
Hinge Health's return on equity (ROE) was −132.9% in fiscal 2025: net income of -$528.3 million on average shareholders' equity of $397.6 million.
How much debt does Hinge Health have?
Hinge Health had total debt of $8.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
Does Hinge Health buy back its shares?
Yes. Hinge Health spent $65.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +4.7% over the year, to 81.7M..
What is Hinge Health's free cash flow yield?
Hinge Health generated $170.7 million of free cash flow in fiscal 2025, a free cash flow yield of 4.5% on its market value at year-end ($3.8 billion).
What is Hinge Health's current ratio?
Hinge Health's current ratio was 1.47 at the end of fiscal 2025: current assets were 1.47 times current liabilities.